On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.